| Literature DB >> 25344395 |
Melina Andrade Mattar, Bruno Gualano, Luiz Augusto Perandini, Samuel Katsuyuki Shinjo, Fernanda Rodrigues Lima, Ana Lúcia Sá-Pinto, Hamilton Roschel.
Abstract
INTRODUCTION: Our aim was to evaluate the safety and efficacy of a low-intensity resistance training program combined with partial blow flow restriction (BFR training) in a cohort of patients with polymyositis (PM) and dermatomyositis (DM).Entities:
Mesh:
Year: 2014 PMID: 25344395 PMCID: PMC4232679 DOI: 10.1186/s13075-014-0473-5
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Flowchart of the protocol for the patients with polymyositis and dermatomyositis.
Patients’ characteristics and drug regimen
|
|
|
|
|
|---|---|---|---|
| I (DM) | 30.5 | 61 | AZA |
| II (DM) | 38.6 | 60 | CQ; MTX; CP |
| III (DM) | 38.2 | 151 | None |
| IV (PM) | 27.9 | 23 | AZA |
| V (DM) | 21.4 | 75 | CQ; CP |
| VI (DM) | 26.5 | 52 | AZA; MTX; Prednisone |
| VII (PM) | 31.4 | 99 | MTX 15 |
| VIII (PM) | 32.4 | 26 | AZA; MTX |
| IX (DM) | 23.5 | 82 | MTX |
| X (DM) | 27.4 | 37 | HCQ; AZA |
| XI (PM) | 25.2 | 38 | MMF |
| XII (DM) | 43.0 | 93 | AZA |
| XIII (DM) | 37.7 | 48 | AZA |
| All patients, mean (SD) | 31 (6.6) | 65 (35) | Not applicable |
DM, dermatomyositis; PM, polymyositis; BMI, body mass index; AZA, azathioprine; CQ, chloroquine diphosphate; MTX, methotrexate; CP, cyclosporine; HCQ, hydroxychloroquine sulphate; MMF, mycophenolate mofetil.
Figure 2Muscle strength and physical function data at baseline (PRE) and after 12 weeks of intervention (POST). (A) Leg-press exercise one-repetition-maximum (1RM) data; (B) knee-extension exercise 1RM data; (C) timed-stands test (TST) data; (D): timed up-and-go test (TUG) data. *P <0.05 when compared with baseline assessments.
Figure 3Quadriceps cross-sectional area (CSA) at baseline (PRE) and after 12 weeks of intervention (POST). *P <0.05 when compared with baseline assessments.
Effects of a 12-week supervised BFR training program on health-related quality of life, limitation of daily activities and laboratory parameters in patients with polymyositis and dermatomyositis
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| SF-36 physical function | 57.5 ± 23.2 | 80.4 ± 11.6 | 1.03 | 39.82 | 0.003* |
| SF-36 role physical | 31.3 ± 42.8 | 62.5 ± 39.2 | 0.76 | 99.68 | 0.041* |
| SF-36 bodily pain | 59.4 ± 11.4 | 86.9 ± 14.8 | 2.52 | 46.29 | 0.002* |
| SF-36 general health | 71.4 ± 20.1 | 83.8 1 ± 5.6 | 0.65 | 17.36 | 0.003* |
| SF-36 vitality | 54.6 ± 20.4 | 84.2 ± 9.3 | 1.52 | 54.21 | 0.003* |
| SF-36 social function | 65.6 ± 33.7 | 89.6 ± 17.5 | 0.74 | 36.58 | 0.017* |
| SF-36 role emotional | 27.8 ± 44.6 | 77.8 ± 38.5 | 1.17 | 179.85 | 0.014* |
| SF-36 mental health | 62.3 ± 20.8 | 79.0 ± 16.9 | 0.83 | 26.80 | 0.007* |
| HAQ | 1.5 ± 1.9 | 0.6 ± 0.6 | −0.49 | −60.00 | 0.004* |
| VAS patient | 3.4 ± 1.4 | 1.6 ± 1.2 | −1.51 | −52.94 | 0.008* |
| VAS physician | 2.6 ± 1.2 | 1.2 ± 0.6 | −1.21 | −53.84 | 0.004* |
PRE (baseline) and POST (after the intervention) values are presented as mean ± SD. BFR, low-intensity resistance training combined with partial blood flow restriction; PM, polymyositis; DM, dermatomyositis; HAQ, health assessment questionnaire; VAS patient, patient-reported visual analog scale; VAS physician, physician-reported visual analog scale. *P <0.05 when compared with baseline assessments.